4.1N Inhibitors
4.1N inhibitors refers to a class of chemical compounds designed to target and modulate the activity of the protein known as 4.1N (also called protein 4.1R, encoded by the EPB41L1 gene). This protein belongs to the 4.1 superfamily, which includes proteins involved in cytoskeletal organization and cell membrane interactions. The 4.1N protein plays a crucial role in the structural integrity and stability of cells, particularly in the context of the erythrocyte membrane, where it helps maintain the biconcave shape and mechanical resilience of red blood cells. In addition to its role in erythrocytes, 4.1N is expressed in various tissues and cell types, where it contributes to cell adhesion, migration, and signaling processes.
4.1N inhibitors are designed to interfere with the function of the 4.1N protein by binding to specific sites or domains on the protein. By doing so, these inhibitors can potentially disrupt the protein's interactions with other cellular components, thereby affecting processes such as cytoskeletal organization, cell adhesion, and signal transduction. These inhibitors are valuable research tools in the study of cellular processes and signal transduction pathways. They allow scientists to investigate the precise roles of 4.1N in various cellular contexts and to gain insights into its involvement in health and disease.
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Imatinib | 152459-95-5 | sc-267106 sc-267106A sc-267106B | 10 mg 100 mg 1 g | $26.00 $119.00 $213.00 | 27 | |
Imatinib inhibits tyrosine kinase activity, targeting the BCR-ABL fusion protein, preventing its activation and signaling. | ||||||
Sorafenib | 284461-73-0 | sc-220125 sc-220125A sc-220125B | 5 mg 50 mg 500 mg | $57.00 $100.00 $250.00 | 129 | |
Sorafenib is a multi-kinase inhibitor that blocks signaling pathways involved in tumor cell proliferation and angiogenesis. I | ||||||
Gefitinib | 184475-35-2 | sc-202166 sc-202166A sc-202166B sc-202166C | 100 mg 250 mg 1 g 5 g | $63.00 $114.00 $218.00 $349.00 | 74 | |
Gefitinib inhibits the epidermal growth factor receptor (EGFR) tyrosine kinase, disrupting downstream signaling pathways | ||||||
Ruxolitinib | 941678-49-5 | sc-364729 sc-364729A sc-364729A-CW | 5 mg 25 mg 25 mg | $251.00 $500.00 $547.00 | 16 | |
Ruxolitinib is a Janus kinase (JAK) inhibitor that blocks signaling pathways in inflammatory diseases and certain types of blood cancer, such as myelofibrosis and polycythemia vera. | ||||||
Vemurafenib | 918504-65-1 | sc-364643 sc-364643A | 10 mg 50 mg | $117.00 $423.00 | 11 | |
Vemurafenib specifically inhibits the mutant BRAF kinase, commonly found in melanoma, leading to a reduction in cancer cell growth. It is used for BRAF V600E mutation-positive melanoma. | ||||||
Ibrutinib | 936563-96-1 | sc-483194 | 10 mg | $156.00 | 5 | |
Ibrutinib targets Bruton's tyrosine kinase (BTK), which plays a crucial role in B-cell signaling. It is used for B-cell malignancies such as chronic lymphocytic leukemia (CLL) and mantle cell lymphoma. | ||||||
Abiraterone | 154229-19-3 | sc-460288 | 10 mg | $276.00 | ||
Abiraterone inhibits the enzyme CYP17A1, reducing the production of androgens in the adrenal glands and tumor cells. | ||||||
Tamoxifen | 10540-29-1 | sc-208414 | 2.5 g | $272.00 | 18 | |
Tamoxifen is a selective estrogen receptor modulator (SERM) that competes with estrogen for binding to the estrogen receptor, studied in the research of estrogen receptor-positive breast cancer. | ||||||
Bortezomib | 179324-69-7 | sc-217785 sc-217785A | 2.5 mg 25 mg | $135.00 $1085.00 | 115 | |
Bortezomib inhibits the proteasome, disrupting protein degradation in cancer cells, leading to apoptosis. It is studied in the research of multiple myeloma and mantle cell lymphoma. | ||||||
Osimertinib | 1421373-65-0 | sc-507355 | 5 mg | $86.00 | ||
Osimertinib selectively targets EGFR mutations (T790M) in NSCLC, inhibiting their activity and suppressing cancer cell growth. It is studied in the research of EGFR-mutated NSCLC. | ||||||